Open Access. Powered by Scholars. Published by Universities.®
Social and Behavioral Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 5 of 5
Full-Text Articles in Social and Behavioral Sciences
Oat Β-Glucan Supplementation Does Not Enhance The Effectiveness Of An Energy-Restricted Diet In Overweight Women, Eleanor J. Beck, Linda C. Tapsell, Marijka J. Batterham, Susan M. Tosh, Xu-Feng Huang
Oat Β-Glucan Supplementation Does Not Enhance The Effectiveness Of An Energy-Restricted Diet In Overweight Women, Eleanor J. Beck, Linda C. Tapsell, Marijka J. Batterham, Susan M. Tosh, Xu-Feng Huang
Faculty of Science, Medicine and Health - Papers: part A
Epidemiological evidence shows an inverse relationship between dietary fibre intake and body weight gain. Oat β-glucan, a soluble fibre alters appetite hormones and subjective satiety in acute meal test studies, but its effects have not been demonstrated with chronic consumption. The present study aimed to test the effects in women of two different doses of oat β-glucan on weight loss and hormones associated with appetite regulation. In a 3-month parallel trial, sixty-six overweight females were randomised into one of three 2 MJ energy-deficit diets: a control and two interventions including 5–6 g or 8–9 g β-glucan. Anthropometric and metabolic variables …
Sensitivity Of The Female Rat To Olanzapine-Induced Weight Gain - Far From The Clinic?, Katrina Weston-Green, Xu-Feng Huang, Chao Deng
Sensitivity Of The Female Rat To Olanzapine-Induced Weight Gain - Far From The Clinic?, Katrina Weston-Green, Xu-Feng Huang, Chao Deng
Faculty of Science, Medicine and Health - Papers: part A
Dear Editor, The recent paper by Chintoh and colleagues (2008) reporting olanzapine-induced dysfunction in glucose metabolism, enhanced visceral fat and reduced locomotor activity in female rats was highly interesting as it illustrated olanzapine’s ability to replicate aspects of metabolic dysfunction in the rodent model in a similar manner to the human scenario. However, contrary to previous reports in the rat and the clinic, the authors reported no change in body weight or food intake following olanzapine treatment, questioning the validity of the rat model.................
Potential Control Of Antipsychotic-Induced Hyperprolactinemia And Obesity In Children And Adolescents By Aripiprazole, J Lian, Xu-Feng Huang, Nagesh Pai, Chao Deng
Potential Control Of Antipsychotic-Induced Hyperprolactinemia And Obesity In Children And Adolescents By Aripiprazole, J Lian, Xu-Feng Huang, Nagesh Pai, Chao Deng
Faculty of Science, Medicine and Health - Papers: part A
The paper published in your journal by Migiliardi et al. (2009) reported that increased hyperprolactinemia is a major side-effect of risperidone and olanzapine treatment in children and adolescents. They showed that risperidone could cause 10 times higher prolactin levels than olanzapine treatment in children and adolescents. This was a well-designed study that controlled for dose, gender, and individual differences, as well as response differences to treatment duration (Migliardi et al. 2009). However, another important issue that should be considered, but was not reported in this study, is antipsychotic-induced weight gain/obesity. Clinical data have demonstrated that weight gain is a major …
What Is The Mechanism For Aripiprazole's Effect On Reducing Olanzapine-Associated Obesity?, Chao Deng, J-Z Chen, Changhua Hu, Xu-Feng Huang
What Is The Mechanism For Aripiprazole's Effect On Reducing Olanzapine-Associated Obesity?, Chao Deng, J-Z Chen, Changhua Hu, Xu-Feng Huang
Faculty of Science, Medicine and Health - Papers: part A
We read with great interest Henderson and colleagues’ paper in your journal (2009; 29:165–169), which reported that aripiprazole reduced olanzapine-induced overweight/obesity and hyperlipidemia in a 10-week placebo-controlled double-blind crossover study. This and their previous studies, provide a new way for controlling olanzapine- and clozapine-induced weight gain/obesity using another atypical antipsychotic, even without reducing the original olanzapine and clozapine doses, which is important particularly for treatment of refractory schizophrenia patients. ....
Lipids And Alzheimer's Disease, Brett Garner
Lipids And Alzheimer's Disease, Brett Garner
Faculty of Science, Medicine and Health - Papers: part A
According to the World Health Organisation (WHO), the number of people suffering from Alzheimer's disease (AD) worldwide is around 18 million. The prevalence of AD doubles every five years between 65 and 85 years of age and it is estimated that due to the ageing population, 34 million people will suffer from AD by 2025. The WHO has also stated that if AD onset were delayed by 5 years, the number of cases worldwide could be halved. Currently there are no curative or disease-stalling treatments for AD and a major research effort is underway in order to better understand the …